Vladislav I.
- Country
- Bulgaria
- Department
- Endocrinology consulting room
Research Overview
- Efficacy and Safety of Zenagamtide in Participants with Obesity: A Randomized Controlled Trial to Evaluate Weight Maintenance
- Evaluation of EDP-938 (Zelicapavir) Efficacy and Safety in Non-Hospitalized Adults with Acute Respiratory Syncytial Virus Infection at High Risk for Complications
- Evaluation of Baxdrostat and Dapagliflozin on Chronic Kidney Disease Progression in Hypertensive Patients: A Randomized, Double-Blind, Active-Controlled Phase III Trial
Data & Insights
Has run more than one trial at 106 of 334 partner sites.
Specializations
Nephrology & Hypertension
The investigator specializes in treating patients with chronic kidney disease (CKD) and hypertension, with particular emphasis on innovative therapeutic combinations for disease management.
- Kidney Function Assessment
- Blood Pressure Management
- eGFR Monitoring
Their research explores treatment strategies to slow CKD progression and improve patient outcomes in complex renal conditions.
Cardiovascular Health
The investigator focuses on cardiovascular complications associated with kidney disease, studying interventions that address both renal and cardiac outcomes.
- Cardiovascular Risk Management
- Combined Therapy Approaches
- Clinical Outcomes Assessment
Their work emphasizes the interconnection between cardiovascular and renal health in treatment strategies.
Infectious Disease
The investigator conducts research in respiratory viral infections, with specific attention to Respiratory Syncytial Virus (RSV) in high-risk adult populations.
- Viral Infection Management
- Clinical Symptom Assessment
- High-Risk Patient Care
Their research addresses therapeutic interventions for non-hospitalized adults with acute RSV infection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.